<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26901482</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.</ArticleTitle><Pagination><StartPage>1678</StartPage><EndPage>1689</EndPage><MedlinePgn>1678-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1143576</ELocationID><Abstract><AbstractText>Dengue has a major impact on global public health, and the use of dengue vaccine is very limited. In this study, we evaluated the immunogenicity and protective efficacy of a dengue vaccine made from a recombinant measles virus (MV) that expresses envelope protein domain III (ED3) of dengue-1 to 4. Following immunization with the MV-vectored dengue vaccine, mice developed specific interferon-gamma and antibody responses against dengue virus and MV. Neutralizing antibodies against MV and dengue viruses were also induced, and protective levels of FRNT50 &#x2265; 10 to 4 serotypes of dengue viruses were detected in the MV-vectored dengue vaccine-immunized mice. In addition, specific interferon-gamma and antibody responses to dengue viruses were still induced by the MV-vectored dengue vaccine in mice that were pre-infected with MV. This finding suggests that the pre-existing immunity to MV did not block the initiation of immune responses. By contrast, mice that were pre-infected with dengue-3 exhibited no effect in terms of their antibody responses to MV and dengue viruses, but a dominant dengue-3-specific T-cell response was observed. After injection with dengue-2, a detectable but significantly lower viremia and a higher titer of anti-dengue-2 neutralizing antibodies were observed in MV-vectored dengue vaccine-immunized mice versus the vector control, suggesting that an anamnestic antibody response that provided partial protection against dengue-2 was elicited. Our results with regard to T-cell responses and the effect of pre-immunity to MV or dengue viruses provide clues for the future applications of an MV-vectored dengue vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hui-Mei</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Graduate Institute of Immunology, China Medical University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Yu-Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Szu-Hsien</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Han-Hsuan</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Chun-Hsiang</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Graduate Institute of Immunology, China Medical University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Chih-Hsiang</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Graduate Institute of Immunology, China Medical University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chien-Hsiung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>a National Institute of Infectious Disease and Vaccinology, National Health Research Institutes , Zhunan Town , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Graduate Institute of Immunology, China Medical University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="Y">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="Y">Drug Carriers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008459" MajorTopicYN="N">Measles virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26901482</ArticleId><ArticleId IdType="pmc">PMC4964840</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1143576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thomas SJ, Endy TP. Vaccines for the prevention of dengue: development update. Hum Vaccin 2011; 7:674-84; PMID:21508679; http://dx.doi.org/10.4161/hv.7.6.14985</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.7.6.14985</ArticleId><ArticleId IdType="pubmed">21508679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy R, Surendran SN. Global climate change and its potential impact on disease transmission by salinity-tolerant mosquito vectors in coastal zones. Front Physiol 2012; 3:198; PMID:22723781; http://dx.doi.org/10.3389/fphys.2012.00198</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2012.00198</ArticleId><ArticleId IdType="pmc">PMC3377959</ArticleId><ArticleId IdType="pubmed">22723781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50; PMID:14903434</Citation><ArticleIdList><ArticleId IdType="pubmed">14903434</ArticleId></ArticleIdList></Reference><Reference><Citation>Innis BL. Antibody responses to dengue virus infection. New York: CAB Int., 1997.</Citation></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-81; PMID:3277268; http://dx.doi.org/10.1126/science.3277268</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3277268</ArticleId><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol 2008; 62:71-92; PMID:18429680; http://dx.doi.org/10.1146/annurev.micro.62.081307.163005</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.62.081307.163005</ArticleId><ArticleId IdType="pubmed">18429680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses 2011; 3:2374-95; PMID:22355444; http://dx.doi.org/10.3390/v3122374</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3122374</ArticleId><ArticleId IdType="pmc">PMC3280510</ArticleId><ArticleId IdType="pubmed">22355444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. T lymphocyte responses to heterologous secondary dengue virus infections. Ann N Y Acad Sci 2009; 1171 Suppl 1:E36-41; PMID:19751400; http://dx.doi.org/10.1111/j.1749-6632.2009.05055.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05055.x</ArticleId><ArticleId IdType="pubmed">19751400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, Lin CF, Yeh TM, Do QH, Vu TQ, et&#xa0;al.. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 2004; 189:221-32; PMID:14722886; http://dx.doi.org/10.1086/380762</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/380762</ArticleId><ArticleId IdType="pubmed">14722886</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr., Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3&#x2032; untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77:1653-7; PMID:12502885; http://dx.doi.org/10.1128/JVI.77.2.1653-1657.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.2.1653-1657.2003</ArticleId><ArticleId IdType="pmc">PMC140839</ArticleId><ArticleId IdType="pubmed">12502885</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74:5477-85; PMID:10823852; http://dx.doi.org/10.1128/JVI.74.12.5477-5485.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.12.5477-5485.2000</ArticleId><ArticleId IdType="pmc">PMC112032</ArticleId><ArticleId IdType="pubmed">10823852</ArticleId></ArticleIdList></Reference><Reference><Citation>Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg 2003; 68:469-76; PMID:12875299</Citation><ArticleIdList><ArticleId IdType="pubmed">12875299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A, et&#xa0;al.. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006; 24:3165-71; PMID:16490289; http://dx.doi.org/10.1016/j.vaccine.2006.01.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.01.036</ArticleId><ArticleId IdType="pubmed">16490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005; 23:3469-76; PMID:15837370; http://dx.doi.org/10.1016/j.vaccine.2004.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.12.028</ArticleId><ArticleId IdType="pubmed">15837370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et&#xa0;al.. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67; PMID:22975340; http://dx.doi.org/10.1016/S0140-6736(12)61428-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61428-7</ArticleId><ArticleId IdType="pubmed">22975340</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et&#xa0;al.. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65; PMID:25018116; http://dx.doi.org/10.1016/S0140-6736(14)61060-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61060-6</ArticleId><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005; 79:1223-31; PMID:15613349; http://dx.doi.org/10.1128/JVI.79.2.1223-1231.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.1223-1231.2005</ArticleId><ArticleId IdType="pmc">PMC538574</ArticleId><ArticleId IdType="pubmed">15613349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, Libraty DH, Gibbons R, Rothman AL. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011; 203:1282-91; PMID:21335561; http://dx.doi.org/10.1093/infdis/jir012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir012</ArticleId><ArticleId IdType="pmc">PMC3069729</ArticleId><ArticleId IdType="pubmed">21335561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, Sette A, Shresta S. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 2010; 185:5405-16; PMID:20870934; http://dx.doi.org/10.4049/jimmunol.1001709</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001709</ArticleId><ArticleId IdType="pmc">PMC2962919</ArticleId><ArticleId IdType="pubmed">20870934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013; 9:e1003723; PMID:24204271; http://dx.doi.org/10.1371/journal.ppat.1003723</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003723</ArticleId><ArticleId IdType="pmc">PMC3814346</ArticleId><ArticleId IdType="pubmed">24204271</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol 2006; 4:900-8; PMID:17088933; http://dx.doi.org/10.1038/nrmicro1550</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1550</ArticleId><ArticleId IdType="pmc">PMC7097605</ArticleId><ArticleId IdType="pubmed">17088933</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, Brahic M, Tangy F. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004; 78:146-57; PMID:14671096; http://dx.doi.org/10.1128/JVI.78.1.146-157.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.1.146-157.2004</ArticleId><ArticleId IdType="pmc">PMC303376</ArticleId><ArticleId IdType="pubmed">14671096</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandler S, Lucas-Hourani M, Moris A, Frenkiel M-P, Combredet C, F&#xe9;vrier M, Bedouelle H, Schwartz O, Despr&#xe8;s P, Tangy F. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007; 1:e96; PMID:18160988; http://dx.doi.org/10.1371/journal.pntd.0000096</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0000096</ArticleId><ArticleId IdType="pmc">PMC2154386</ArticleId><ArticleId IdType="pubmed">18160988</ArticleId></ArticleIdList></Reference><Reference><Citation>del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 2007; 81:10597-605; PMID:17634218; http://dx.doi.org/10.1128/JVI.00923-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00923-07</ArticleId><ArticleId IdType="pmc">PMC2045491</ArticleId><ArticleId IdType="pubmed">17634218</ArticleId></ArticleIdList></Reference><Reference><Citation>Blechacz B, Russell SJ. Measles virus as an oncolytic vector platform. Curr Gene Ther 2008; 8:162-75; PMID:18537591; http://dx.doi.org/10.2174/156652308784746459</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652308784746459</ArticleId><ArticleId IdType="pubmed">18537591</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandler S, Ruffie C, Najburg V, Frenkiel M-P, Bedouelle H, Despr&#xe8;s P, Tangy F. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010; 28:6730-9; PMID:20688034</Citation><ArticleIdList><ArticleId IdType="pubmed">20688034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, Murphy KM, Schreiber RD, Diamond MS. A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog 2011; 7:e1002407; PMID:22144897; http://dx.doi.org/10.1371/journal.ppat.1002407</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002407</ArticleId><ArticleId IdType="pmc">PMC3228803</ArticleId><ArticleId IdType="pubmed">22144897</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol 2010; 84:3798-807; PMID:20130066; http://dx.doi.org/10.1128/JVI.01566-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01566-09</ArticleId><ArticleId IdType="pmc">PMC2849488</ArticleId><ArticleId IdType="pubmed">20130066</ArticleId></ArticleIdList></Reference><Reference><Citation>Borras E, Urbiztondo L, Costa J, Batalla J, Torner N, Plasencia A, Salleras L, Dominguez A, Working Group for the Study of Measles Immunity in C. Measles antibodies and response to vaccination in children aged less than 14 months: implications for age of vaccination. Epidemio Infect 2012; 140:1599-606; PMID:22074684; http://dx.doi.org/10.1017/S0950268811002184</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268811002184</ArticleId><ArticleId IdType="pubmed">22074684</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Despres P, Tangy F. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013; 31:3718-25; PMID:23742993; http://dx.doi.org/10.1016/j.vaccine.2013.05.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.086</ArticleId><ArticleId IdType="pubmed">23742993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, et&#xa0;al.. Attenuated measles virus as a vaccine vector. Vaccine 2007; 25:2974-83; PMID:17303293; http://dx.doi.org/10.1016/j.vaccine.2007.01.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.01.064</ArticleId><ArticleId IdType="pmc">PMC3707277</ArticleId><ArticleId IdType="pubmed">17303293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009; 392:103-13; PMID:19631955; http://dx.doi.org/10.1016/j.virol.2009.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998; 72:7420-7; PMID:9696838</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109970</ArticleId><ArticleId IdType="pubmed">9696838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka A, Konishi E. A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells. Vaccine 2009; 27:3735-43; PMID:19464557; http://dx.doi.org/10.1016/j.vaccine.2009.03.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.083</ArticleId><ArticleId IdType="pubmed">19464557</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Hsieh CH, Chen MY, Tsai JP, Liu HH, Liu SJ, Chong P, Leng CH, Chen HW. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine 2014; 32:1346-53; PMID:24486311; http://dx.doi.org/10.1016/j.vaccine.2014.01.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.01.041</ArticleId><ArticleId IdType="pubmed">24486311</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 2006; 24:2200-7; PMID:16316713; http://dx.doi.org/10.1016/j.vaccine.2005.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.11.002</ArticleId><ArticleId IdType="pubmed">16316713</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, Kolla RV, De Silva AD, de Silva AM, Grey H, et&#xa0;al.. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol 2011; 187:4268-79; PMID:21918184; http://dx.doi.org/10.4049/jimmunol.1101970</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101970</ArticleId><ArticleId IdType="pmc">PMC3186824</ArticleId><ArticleId IdType="pubmed">21918184</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda M, Ohno S, Seki F, Hashimoto K, Miyajima N, Takeuchi K, Yanagi Y. Efficient rescue of measles virus from cloned cDNA using SLAM-expressing Chinese hamster ovary cells. Virus Res 2005; 108:161-5; PMID:15681066; http://dx.doi.org/10.1016/j.virusres.2004.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2004.09.002</ArticleId><ArticleId IdType="pubmed">15681066</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng C-H, Liu S-J, Tsai J-P, Li Y-S, Chen M-Y, Liu H-H, Lien S-P, Yueh A, Hsiao K-N, Lai L-W, et&#xa0;al.. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 2009; 11:288-95; PMID:19114121; http://dx.doi.org/10.1016/j.micinf.2008.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2008.12.004</ArticleId><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 2008; 15:1214-21; PMID:18524884; http://dx.doi.org/10.1128/CVI.00120-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00120-08</ArticleId><ArticleId IdType="pmc">PMC2519314</ArticleId><ArticleId IdType="pubmed">18524884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Pan CH, Hsieh CH, Tsai JP, Chen MY, Liu HH, Liu SJ, Chong P, Leng CH, Chen HW. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis 2013; 7:e2432; PMID:24069487; http://dx.doi.org/10.1371/journal.pntd.0002432</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002432</ArticleId><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="pubmed">24069487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>